In a first, US scientists have used stem cells to grow human oesophagus -- known as the food pipe -- in the laboratory, an advance that will enable personalised disease diagnosis, regenerative therapies.
A team from the Cincinnati Children's Hospital in Ohio successfully generated fully formed human oesophageal organoids -- tiny version of an organ produced in vitro in three dimensions -- using pluripotent stem cells (PSCs).
PSCs are master cells that can potentially produce any cell or tissue the body needs to repair itself.
The oesophageal organoids grew to a length of about 300-800 micrometers in about two months.
"Disorders of the oesophagus and trachea are prevalent enough in people that organoid models of human oesophagus could be greatly beneficial," said lead investigator Jim Wells, from the hospital.
"In addition to being a new model to study birth defects like oesophageal atresia, the organoids can be used to study diseases like oeosinophilic oesophagitis and Barrett's metaplasia, or to bioengineer genetically matched oesophageal tissue for individual patients," he added.
In the study, published in the journal Cell Stem Cell, the team focused on the gene Sox2 and its associated protein -- known to trigger oesophageal conditions when their function is disrupted.
The scientists used mice, frogs and human tissue cultures to identify other genes and molecular pathways regulated by Sox2 during oesophagus formation.
During critical stages of embryonic development, the Sox2 gene blocks the programming and action of genetic pathways that direct cells to become respiratory instead of oesophageal.
The Sox2 protein inhibits the signalling of a molecule called Wnt and promotes the formation and survival of oesophageal tissues.
Conversely, the absence of Sox2 during the development process in mice can result in oesophageal agenesis -- a condition in which the oesophagus terminates in a pouch and does not connect to the stomach.
Those tests showed the bioengineered and biopsies tissues were strikingly similar in composition, the team said.
Cincinnati Children's scientists have previously used PSCs to bioengineer human intestine, stomach, colon and liver.
--IANS
rt/mag/sed
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
